May 2005
Volume 46, Issue 13
ARVO Annual Meeting Abstract  |   May 2005
Clinical Efficacy of Olopatadine and Epinastine in Allergic Conjunctivitis Subjects Defined by Sensitivity to Conjunctival Allergen Challenge (CAC)
Author Affiliations & Notes
  • P.A. D'Arienzo
    St. Vincent Catholic Medical Center, Flushing, NY
  • D. Granet
    Director & Surgeon Chief, Pediatric Ophthalmology, Ratner Childrens' Eye Center, UCSD, San Diego, CA
  • A.B. Epstein
    N. Shore University Hospital NYU School of Medicine, Great Neck, NY
  • B.Q. Lanier
    Ft. Worth Allergy & Asthma Association, Ft. Worth, TX
  • I. Finegold
    Division of Allergy & Immunology, St. Luke's–roosevelt Hospital Center, New York, NY
  • G.L. Ledgerwood
    Clincal Assistant Professor, University of Washington Medical School, Seattle, WA
  • Footnotes
    Commercial Relationships  P.A. D'Arienzo, None; D. Granet, None; A.B. Epstein, None; B.Q. Lanier, None; I. Finegold, None; G.L. Ledgerwood, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 2677. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      P.A. D'Arienzo, D. Granet, A.B. Epstein, B.Q. Lanier, I. Finegold, G.L. Ledgerwood; Clinical Efficacy of Olopatadine and Epinastine in Allergic Conjunctivitis Subjects Defined by Sensitivity to Conjunctival Allergen Challenge (CAC) . Invest. Ophthalmol. Vis. Sci. 2005;46(13):2677.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements


To evaluate the effects of olopatadine 0.1% and epinastine 0.05% ophthalmic solutions on the prevention of ocular itching in individuals of varying allergic sensitivity. Olopatadine is approved for treatment of all signs and symptoms of allergic conjunctivitis, and epinastine for itching. Therefore, this study focused on symptom comparison.


This was a prospective, randomized, double–masked, contalaterally–controlled, single center, 3–visit CAC study. Allergen titration was conducted at Visit 1 and confirmation of ocular allergic reaction at Visit 2. Sixty–six subjects were randomized by eye at Visit 3 to receive olopatadine, epinastine, or placebo. CAC was administered 5 min post medication administration. Itching was evaluated at 3, 5, & 7 min post–CAC on a standardized scale (0–4). Analysis was performed to rank subjects by level of ocular itching experienced at Visit 2 (untreated CAC), into moderate, moderate/severe, and severe categories. Mean scores from eyes of subjects receiving olopatadine in one eye and epinastine in the fellow eye were calculated according to severity; statistical significance was measured by a 2–tailed Wilcoxon rank–sign test.



Olopatadine treated eyes exhibited lower itching scores than epinastine in all three levels of severity; (moderate: n=11; moderate/severe: n=14 severe: n=19). Greatest differences occurred in subjects in the severe category:




Results indicate that olopatadine exhibits significantly greater prevention of the ocular allergic reaction in high–severity allergy sufferers, as compared to epinastine.


Keywords: conjunctiva • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled • conjunctivitis 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.